In the goal of increasing market opportunities for its biotech innovations, Rainbow Coral is now looking for new overseas targets that could benefit from adding licenses for the drug delivery protocols that its joint venture partner, TheraKine, has developed.
According to some experts, the worldwide market for the 10 most popular drug delivery technologies (DDTs) alone could grow to $81.5 billion by 2015. TheraKine is a leader in this space, having developed and patented novel, tunable technologies with the potential to enable selective, site-specific drug delivery. These technologies promise to lower drug concentrations and significantly reduced risk of drug toxicity.
Focused on building market share in this fast-growing sector, RBCC is targeting overseas healthcare providers for whom TheraKine’s advanced sustained-release delivery system could yield significant returns for their clients.
“Licensing is the key to making this a successful partnership with TheraKine,” said RBCC CEO Patrick Brown. “Together, we can spread this revolutionary technology around the globe to the doctors and patients who need it most.”
For more information on Rainbow BioSciences’ personalized medicine initiatives, please visit www.rainbowbiosciences.com/investors.html
Let us hear your thoughts: Rainbow Coral Corp. Message Board